📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Vaishali Pharma Shareholders Approve Preferential Issue of Equity Shares
Vaishali Pharma Limited has received shareholder approval through a postal ballot for the issuance and allotment of equity shares on a preferential basis. The special resolution was passed with an overwhelming majority, with 99.99% of the votes cast in favor by participating public shareholders. Promoters and the promoter group abstained from voting as they were interested parties in the resolution. This approval clears the path for the company to raise capital, which is typically used for expansion or strengthening the balance sheet.
Key Highlights
Special Resolution for issuing equity shares on a preferential basis was approved by shareholders.
The resolution received 99.9909% votes in favor from the public non-institutional category.
A total of 25,415,321 votes were polled during the postal ballot process.
Promoters and promoter group members abstained from voting due to their interest in the resolution.
The record date for determining eligibility for the postal ballot was February 6, 2026.
💼 Action for Investors
Investors should monitor upcoming disclosures regarding the specific allotment price and the list of allottees to evaluate the impact of equity dilution. The successful approval indicates strong shareholder support for the company's fundraising and growth plans.
Vaishali Pharma to Acquire 51.02% of Kesar Pharma; Preferential Issue at Rs 20 Per Share
Vaishali Pharma has issued a corrigendum to its postal ballot notice regarding the acquisition of a 51.02% stake in Kesar Pharma Limited. The deal involves a preferential issue of shares at Rs 20 each, which is significantly higher than the SEBI-mandated floor price of Rs 09.46. The floor price was derived from the 90-day volume-weighted average price (VWAP) as per regulatory requirements. Shareholders have until March 15, 2026, to cast or modify their votes based on these updated disclosures.
Key Highlights
Proposed acquisition of a 51.02% majority stake in Kesar Pharma Limited
Preferential shares to be issued at Rs 20 per share, a 111% premium over the floor price of Rs 09.46
Floor price based on 90-day VWAP of Rs 09.46 and 10-day VWAP of Rs 08.02
Relevant date for the transaction pricing is February 13, 2026
E-voting facility for shareholders is open until 05:00 PM on March 15, 2026
💼 Action for Investors
Investors should monitor the successful integration of Kesar Pharma as it represents a significant majority acquisition. The high issue price relative to the floor price is a positive signal regarding the company's internal valuation.
Vaishali Pharma to Issue 61.23 Lakh Shares for 33.24% Stake in Kesar Pharma
Vaishali Pharma Limited has issued a postal ballot notice to seek shareholder approval for a preferential allotment of 61.23 lakh equity shares. The shares are priced at Rs. 20 each, representing a total transaction value of approximately Rs. 12.25 crores. This is a non-cash transaction involving a share swap to acquire a 33.24% stake in Kesar Pharma Limited, an associate company. The e-voting period for shareholders is scheduled from February 14 to March 15, 2026.
Key Highlights
Preferential issue of up to 61,23,000 equity shares at an issue price of Rs. 20 per share
Total consideration of Rs. 12.25 crores to be settled via share swap (non-cash)
Acquisition of 21,52,575 shares in Kesar Pharma Limited, representing a 33.24% stake
Relevant date for floor price determination fixed as February 13, 2026
E-voting results to be announced on or before March 17, 2026
💼 Action for Investors
Investors should assess the strategic value of consolidating the stake in Kesar Pharma against the equity dilution caused by the new share issuance. Monitor the final approval and subsequent integration of Kesar Pharma's operations.
Vaishali Pharma Approves Rs 12.25 Cr Share Swap for Kesar Pharma Stake
Vaishali Pharma has approved the issuance of 61.23 lakh equity shares at Rs 20 each via a preferential allotment. This is a non-cash transaction involving a share swap to acquire 21.52 lakh shares of its associate company, Kesar Pharma Limited, at Rs 56.89 per share. The total value of the issuance is approximately Rs 12.25 Crores, resulting in Kesar Pharma holding a 4.48% stake in the company. Additionally, the board has cleared the unaudited financial results for the quarter and nine months ended December 31, 2025.
Key Highlights
Issuance of 61,23,000 equity shares at a price of Rs 20 per share
Total deal value of Rs 12.246 Crores via share swap for Kesar Pharma stake
Acquisition of 21,52,575 shares of Kesar Pharma Limited at Rs 56.89 per share
Post-allotment, Kesar Pharma Limited will own 4.48% of Vaishali Pharma
Board approved Q3 FY26 results and initiated a postal ballot for shareholder approval
💼 Action for Investors
Investors should evaluate the valuation of Kesar Pharma and the impact of the 4.48% equity dilution on earnings per share. Watch for the detailed Q3 financial performance to assess the company's growth trajectory.
Vaishali Pharma to Issue 61.23 Lakh Shares via Swap for Kesar Pharma Stake
Vaishali Pharma has approved a preferential allotment of 61.23 lakh equity shares at an issue price of ₹20 per share, totaling approximately ₹12.25 crores. This is a non-cash transaction executed via a share swap to subscribe to 21.53 lakh shares of its associate company, Kesar Pharma Limited, at ₹56.89 per share. Post-allotment, Kesar Pharma will hold a 4.48% stake in Vaishali Pharma. The board also approved the unaudited financial results for the quarter ended December 31, 2025.
Key Highlights
Preferential issue of 61,23,000 equity shares at ₹20 each (including ₹18 premium).
Total transaction value for the share swap is ₹12,24,60,000.
Acquisition of 21,52,575 shares of associate company Kesar Pharma Limited at ₹56.89 per share.
Post-issue, Kesar Pharma Limited will hold a 4.48% equity stake in Vaishali Pharma.
Board approved Q3 FY26 financial results and initiated a Postal Ballot for shareholder approval.
💼 Action for Investors
Investors should monitor the strategic benefits of increasing the stake in Kesar Pharma and review the Q3 financial results for operational performance. The share swap indicates a consolidation of interests with its associate company.
Vaishali Pharma to Issue Shares Worth ₹12.25 Cr via Swap for Kesar Pharma Stake
Vaishali Pharma's board has approved a preferential allotment of 61.23 lakh equity shares at ₹20 per share, totaling ₹12.25 crore. This is a non-cash transaction executed via a share swap to acquire 21.53 lakh shares of its associate company, Kesar Pharma Limited, at ₹56.89 per share. The board also cleared the unaudited financial results for the quarter ended December 31, 2025. This move will result in Kesar Pharma Limited holding a 4.48% stake in Vaishali Pharma post-allotment.
Key Highlights
Issuance of 61,23,000 equity shares at ₹20 per share aggregating to ₹12.246 Crores.
Transaction involves a share swap for 21,52,575 shares of associate company Kesar Pharma.
Kesar Pharma Limited to hold 4.48% post-issue equity in Vaishali Pharma.
Board approved Q3 and 9M FY26 financial results during the same meeting.
Relevant date for floor price determination set as February 13, 2026.
💼 Action for Investors
Investors should review the Q3 financial performance and assess the strategic value of increasing the stake in Kesar Pharma. Monitor the upcoming postal ballot results for shareholder approval of this preferential issue.